8-K filed Jun 15, 2026 at 08:01 ET
Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 (anti-TL1A) in moderate-to-severe ulcerative colitis. The primary endpoint was met with a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), with clinical remission of 33% and endoscopic improvement of 42%. Safety was consistent with the TL1A class with no drug-related serious adverse events. This de-risks SPY002 and supports the ongoing Part B randomized portion and combination arms.